Specificbiologics
Founded 2017 · 16 employees on LinkedIn · 1 known investors
Specific Biologics develops in vivo genome editing therapeutics based on its Dualase editors, which use a two-site mechanism to remove, repair, or insert DNA sequences, with an initial focus on correcting expanded DNA repeats. Its pipeline targets CNS, lung, and liver genetic diseases using single AAV or lipid nanoparticle/polymer-encapsulated all-RNA delivery.
Investors · 1
Competitors · 2
by search overlap
Cellectis3 shared keywordsCellectis is a gene-editing company that uses its TALEN technology to engineer CAR T-cells from healthy donors into "off-the-shelf" allogeneic immunotherapy candidates aimed at treating cancer and potentially other diseases. It develops therapies designed to be broadly available rather than custom-made per patient.
BioCytics3 shared keywordsBioCytics conducts translational cancer research, including a project with UNC Charlotte and Carolina BioOncology Institute to study the "dark genome" of cancer cells to identify sequences involved in tumor growth, immune response, and treatment response. Its work spans cell therapy, neoantigens, tumor infiltrating lymphocytes, and clinical research informatics.
Companies competing with Specificbiologics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Specificbiologics do?
- Specific Biologics develops in vivo genome editing therapeutics based on its Dualase editors, which use a two-site mechanism to remove, repair, or insert DNA sequences, with an initial focus on correcting expanded DNA repeats. Its pipeline targets CNS, lung, and liver genetic diseases using single AAV or lipid nanoparticle/polymer-encapsulated all-RNA delivery.
- Who are Specificbiologics's investors?
- Specificbiologics's investors include Lumira Ventures.